Division of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Division of Gastroenterology, Northern Jiangsu People's Hospital, Yangzhou, China.
Neuromodulation. 2020 Dec;23(8):1180-1188. doi: 10.1111/ner.13158. Epub 2020 May 6.
Gastrointestinal (GI) disturbances occur in patients who receive chemotherapy via transcatheter arterial chemoembolization (TACE) and could last for an extended period of time in some cases. Antiemetic drugs have a potential risk of developing hepatic failure and are ineffective for delayed nausea and emesis. Transcutaneous electrical acustimulation (TEA) has recently been reported to exert antiemetic and prokinetic effects, but it is unknown whether it has an ameliorating effect on TACE-induced GI disturbances.
This study was designed to evaluate effects and mechanisms of noninvasive TEA on GI symptoms in patients treated with TACE.
Seventy-four patients with liver cancers (eighteen female; age 63.4 ± 1.1 years) scheduled for TACE were randomized to TEA (n = 37) or sham-TEA (n = 37). TEA was performed via acupoints, ST36 and PC6 using parameters previously optimized for GI motility (1 h, bid) from the postoperative day 0 (POD0) to POD2. Sham-TEA was performed using the same parameters via non-acupoints. Symptom questionnaires were completed daily. The electrogastrogram (EGG) and electrocardiogram (ECG) were recorded in the fasting state for 30 mins to assess gastric slow waves and autonomic functions, respectively, before and after the 3-day treatment.
TEA improves major TACE-induced GI disturbances in the delayed phase, including nausea, bloating, impaired gastric pace-making activity, and constipation in patients with liver cancers via the autonomic pathway.
接受经导管动脉化疗栓塞术(TACE)治疗的患者会出现胃肠道(GI)紊乱,在某些情况下可能会持续很长时间。止吐药物有发生肝衰竭的潜在风险,并且对迟发性恶心和呕吐无效。经皮电刺激(TEA)最近被报道具有止吐和促动力作用,但尚不清楚其是否对 TACE 引起的 GI 紊乱有改善作用。
本研究旨在评估非侵入性 TEA 对 TACE 治疗患者 GI 症状的影响及其机制。
74 例肝癌患者(18 名女性;年龄 63.4±1.1 岁)拟行 TACE 治疗,随机分为 TEA 组(n=37)或 sham-TEA 组(n=37)。TEA 通过 ST36 和 PC6 穴位以先前优化的胃肠道动力参数(1h,bid)进行,从术后第 0 天(POD0)至 POD2。 sham-TEA 通过非穴位以相同参数进行。每天完成症状问卷。在治疗前和治疗后 3 天内,在禁食状态下记录 30 分钟的胃电图(EGG)和心电图(ECG),以评估胃慢波和自主神经功能。
1)在急性期(<24 小时),与 sham-TEA 相比,TEA 对任何 GI 症状均无影响。2)在延迟期(>24 小时),与 sham-TEA 相比,TEA 降低了 POD3 时出现恶心的患者比例(0%比 13.5%,p=0.021)、POD3 时的恶心评分(p=0.022)、POD2 和 POD3 时的厌食评分(p=0.040 和 p=0.004)以及腹胀评分(POD1-3:p<0.01)。3)与 sham-TEA 相比,TEA 增加了自发性肠蠕动次数(p=0.001)和首次排便的布里斯托评分(p=0.014),减少了使用泻药的患者人数(p=0.022)。4)生理上,3 天 TEA 但不是 sham-TEA 增加了正常胃慢波的百分比(p<0.001)和迷走神经活动(p=0.006)。迷走神经活动与厌食评分呈负相关(r=-0.267,p=0.026)。研究发现,交感神经-迷走神经比值和肿瘤大小>5cm 是预测 TACE 后患者发生恶心的独立危险因素。
TEA 通过自主神经通路改善了肝癌患者 TACE 后延迟期的主要 GI 紊乱,包括恶心、腹胀、胃起搏活动受损和便秘。